Roth Capital Downgrades Acer Therapeutics to Neutral, Maintains $1.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth Capital analyst Jonathan Aschoff has downgraded Acer Therapeutics (NASDAQ:ACER) from Buy to Neutral, while maintaining a $1.5 price target.
September 01, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acer Therapeutics has been downgraded from Buy to Neutral by Roth Capital, with a maintained price target of $1.5.
The downgrade from Buy to Neutral by Roth Capital indicates a less optimistic outlook for Acer Therapeutics, which could potentially lead to a decrease in the stock's price in the short term. However, the maintained price target of $1.5 suggests that the analyst still sees some value in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100